Sinopharm Holdings (01099), Sinopharm Group and Sinopharm Co., Ltd. plan to sell a total of 51% of Guorui Pharmaceutical's shares for 406 million yuan

Zhitong Finance App News, Sinopharm Holdings (01099) issued an announcement. On August 19, 2026, Sinopharm Group and Sinopharm Co., Ltd. jointly entered into an equity transfer agreement with Sinopharm Hyundai. According to this, (i) the Company agreed to sell 30.13% of the company's target company Sinopharm Group Guorui Pharmaceutical Co., Ltd. (Guorui Pharmaceutical) at a cost of RMB 240 million; (ii) Sinopharm Shares (a subsidiary of the Company) agreed to sell 12.06% of its target company shares to Sinopharm Hyundai at a cost of RMB 12.09.60360,60,603 10,000 Yuan; and (iii) Sinopharm Group agreed to sell 8.81% of its target company shares to Sinopharm Hyundai at a cost of RMB 70,1973 million. The total cost of the transfer of 51% of the above shares was RMB 406 million.

After the share transfer is completed, the target company will no longer be a consolidated subsidiary of the Company. The Company will no longer directly hold any shares in the target company.

After the transaction is completed, Guorui Pharmaceutical will become a holding subsidiary of Sinopharm Hyundai, which will help eliminate competition in the industry, optimize the Group's asset structure and internal resource allocation, and promote the integration and collaborative development of the pharmaceutical manufacturing sector, which is in line with the Group's overall development strategy and the overall interests of the Company and its shareholders.